All Flashcards
Celiac artery branches
CHA- RGA, proper hepatic, GDA (RGE and SPD)
LGA
Splenic- LGE
Killians triangle (dz and borders)
Zenkers
Inferior constricter mm
Cricopharyngeus
MC esophageal perforation
MC iatrogenic perfortation
MC- at GE jxn (usu left) (Boerhaaves)
Iatrogenic- cricopharyngeus
DES vs nutcracker
DES- uncoordinated peristalsis
Nutcracker- coordinated high amp contractions
Heller myotomy incision
2cm stomach
6cm esophagus
Tx achalasia v DES v nutracker
Achalasia- Heller first (dilation or botox if poor sx candidate
DES/Nutracker- CCB and nitrates (long segment myotomy if uncontrolled)
Zenkers v epiphrenic v midesophageal- type, etiology, tx
Zenkers- pulsion, failed cricopharyngeal relax, divide cricopharyngeus (+/- remove diverticulum)
Epiphrenic- pulsion, motility DO, diverticulectomy and tx motility DO
Mid- full thickness, inflammatory DO (TB, malignancy), VATS and diverticulectomy
Esophageal CA staging
T1a mucosa (EMR if low grade)
T1b submucosa
T2 muscular
T3 adventitia
N1 1-2
N2 3-6
N3 >7
Proximal esophageal CA managmeent
> 5cm from cricopharyngeus- esophagectomy
<5cm from cricopharyngeus- definitive chemorads
Tylosis
palmar thickening (keratomas)- risk for esophageal SCC
Fanconi anemia
SCC esophagus
SCC H&N
pancytopenia
Stomach ulcer classification
I lesser curve II x2 (1 gastric and 1 prepyloric) III prepyloric IV GE jxn V NSAIDs
II and III are d/t high acid output
Siewert classification
I 1-5cm above GEJ
II 1 above and 2cm below GEJ
III <2cm below GEJ
III is the worst prognosis
Forest classification and rebleed risk
IA- brisk bleeding (80%) IB- oozing IIA- visible vessel (50%) IIB- adherent clot (25%) III- clean ulcer (<5%)
Early and late dumping
Early- 20-30min osmolar load
Late- 1-4hr insulin surge
Afferent loop syndrome- acute vs chronic
Acute- jaundice, duodenal stump blowout – > emergent surg
Chronic- bacterial overgrowth, B12 deficiency, steatorrhea –> abx, then surgery
CDH1 mutation
Autosomal dom
familial gastric cancer (also breast CA)
>18 yo –> prophylactic gastrectomy
Genes: Lynch Juvenile polyposis Peutz Jeugers FAP
Lynch-MMR
Juvenile- SMAD4
Peutz Jeugers- STK11
FAP- APC
Gastric cancer staging
T1a mucosa T1b submucosa T2 muscularis T3 submucosa T4 past submucosa
N1 1-2
N2 3-6
N3 >7
Neoadju for T2 and higher or any nodes (same as esophagus)
Adju for T3 or higher or any nodes
gastric cancer margins, nodes
5cm (4cm per NCCN)
15nodes
Howell Jolly- Pappenheimer- Target cells Spur cells- Heinz-
Howell Jolly- nuclear remnants Pappenheimer- iron deposits Target cells- immature Spur cells- deformed membbranes Heinz- denatured proteins
highest risk for post splenectomy sepsis
beta thalasemia
TTP symptoms
FAT RN
fever, anemia, thrombocytopenia, renal failure, neuro changes
Replaced right and left hepatic a
Right- SMA (behind panc and CBD)
Left- left gastric (gastrohepatic lig)
Rigler triad
bowel obstruction
Stone on imaging
Pneumobilia
gallbladder polyp
> 6mm serial ultrasound
10mm chole
Stone + polyp - chole
1.8cm suspicious for cancer
gallbladder cancer RF and staging
typhoid, PSC, IBD
T1a lamina propria only
T1b muscularis propria - radical cholecystectomy and portal LAD
isolate gastric varices?
splenic v thrombosis (from pancreatitis), tx w splenectomy
portosystemic shunts- pros and cons
splenorenal- (wont help w ascites)
portocaval- may make encephalopathy worse and may mess w transplant options
Pyogenic
Amebic
Echinococcal
Pyogenic- e coli, drain abx
Amebic- serology dx, flagyl (don’t drain!)
Echinococal- double wall, serology dx, albendazole and excise
MELD vs Child Pugh
Child (liver only)- bili, albumin, PT, enceph, ascites
MELD (liver and kidney)- bili, INR, creat (>15 transplant)
Todani classification (and treatment)
1 fusiform (hepaticoJ) 2 saccular diverticulum CBD (RNY choledochojeju) 3 intraduodenal (transduodenal excision, sphincterotomy) 4a intra and extra (hepatic resection, hepaticoJ) 4b extra only (hepaticoJ) 5 intra only (transplant)
Hemangioma v FNH v Adenoma v HCC
Hemangioma- “peripheral nodular enhancement” (peripheral to centripetal enhancement), no washout
FNH- stellate scar, arterial homogenous enhancement, kupffer cell uptake
Adenoma- OCP, 10% malignant, >5cm rupture…same imaging as FNH
HCC- hyperdense w fast washout
Kasabach Merritt syndrome
Hemangioma DIC
MC liver cancer met
Lung
Liver resection percents
Healthy 20%
Mild cirrhosis 30%
Cirrhosis 40%
Sig liver dz 50%
Fibrolamellar liver CA
young, better prognosis
neurotensin marker
Milan criteria
<5cm
<3cm x3
no vascular or extra hepatic spread
Colorectal mets to liver- full response
resect still
RAAS pathway
Renin (kidney) converts angiotensinogen (liver) –> angiotensin I
ACE (lung) converts angiotensin I –> II
Induces aldosterone production
Medical treatment for hyperaldosterone 2/2 adrenal hyperplasia
Spironolactone
Eplrenone
Incidentaloma labs and imaging
cortisol (MN salivary, then 24 hr urine) catecholamines (plasma, then urine) Aldoesterone, renin DHEA (if ACC suspected) urine androgens (if ACC suspected)
> 10 HF units
<60% washout
6cm
adrenocortical carcinoma- chemo
mitotane
Pheo rule of 10%
extraadrenal (MC organ of zuckerkandl at aortic bifurcation) bilateral chidlren familial (VHL, MEN2, NF) malignant
Pheo imaging
CT
MIBG scan if not confirmatory
Stress dose steroids
20mg>3wks (none if <3weeks)
none if <5mg/day
MTC in MEN2 thyroidectomy?
ppx thyroidectomy at 5yo
pseudocyst intervention criteria
> 6cm
symptomatic
enlarging
chronic pancreatitis procedures
Puestow- pancreaticoJ
Beger- head resect and pancreaticoJ
Frey- head excavation and pancreaticoJ
“fish mouth papilla”
main duct pancreatic duct
branch IPMN- high risk features
>3cm thick wall nonenhancing nodules LAD main duct >10mm abrupt main duct change
PNET- symptoms, w/u, management
PET>somatostatin scan
Insulinoma- no somatostatin scan, diazoxide for med management; >2cm formal resection
Gastrinoma- >1000 or secretine stim test >200
Glucagonoma- 4D (dermatitis, DM, depression, DVT)
Somatostatinoma- DM, gallstones, steatorrhea
VIPoma- WDHA syndrome
chole if malignant (somatostatin as chemo)
Pancreatiic cancer genes
p53
KRAS
Pancreatic cancer resectibility
resectable- no arterial contact, <180 SMV or PV
borderline- <180 SMA or celiac, CHA only (no celieac or HAP), reconstructible vein
nonresectable- >180 MSA or celiac
Pancreatic cancer chemo
FOLFIRINOX (folinic acid, 5FU, oxetecan/irenotecan, oxaliplatin)
dentate line- separates?
upper 2/3 from lower 1/3 of anal canal
columnar (upper) vs squamous (lower)
internal v external hemorrhoids
UC vs crohn’s characteristics
UC- crypt abscesses, mucosal
Crohns- fat grandma skipped down wrecked cobbleston; transmural; erythema nodosum
IBD screening
8-10 years after dz onsent
then q1-3 yrs
4quad bx q10cm
high risk colorectal cancer screening
x1 primary CRC <60yo
x2 primary CRC any age - 40yo, q5y
x1 primary CRC >60yo
x2 secondary CRC any age - 40yo, q10y
FAP 10-12yo q1y
HNPCC 20-25yo, q1-2y
FAP v HNPCC- inheritence, gene, dz
FAP- AD, APC, duodenal polyps
HNPCC- AD, MMR, ovarian, endom, bladder, stomach
Amsterdam criteria
3 relatives (one is primary relative of other)
2 generations
1 CA<50yo
Cscope adenoma screening f/u
tubular adenoma <2x <0.5cm- 5yr
tubular adenoma >3 - 3yr
high risk adenoma >1cm, villous, or high grade- 3yr
hyperplastic - 10yr
Malignant polyps- polypectomy ok?
1piece
margins clear
well or mod differentiation
<2mm past mucosa muscularis (if sessile, no submucosal involvement)
colorectal cancer staging
Tis lamina propria
T1 submucosa
T2 muscular propria
T3 serosa
T3 stage 2 - rectal neoadju chemoXRT and adju chemo (xtra neoadju chemo if CRM involved b/f surg)
N1 stage 3 - colon adju chemo
N1 - 1-3
N2 3-6
N3 >7
rectal cancer margins
2cm distal and 5cm proximal
Neoadju and adju chemorads in CRC
Neoadju- 5000 gray, 5FU x 5 weeks
Adju- FOLFOX folinic acid, 5FU, oxaliplatin